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Introduction. Survival rates are a tool that allows evaluation of healthcare quality and cancer treatment efficiency. 
The main aim of this article is to present tendencies in curability of Polish patients diagnosed between 1999–2010 
and followed up until the end of 2015.
Materials and methods. Survival analysis was performed using data from the Polish National Cancer Registry and 
Statistics Poland. The survival rates were calculated using Hakulinen method.
Results. In Poland, five-year survival rates in men for all cancers increased from 32.9% (diagnosis 1999–2001) to 41.3% 
(diagnosis 2008–2010), whereas in women, from 50.9% to 56.1% respectively. The biggest improvement was found 
in therapy of prostate cancer (by 15.5 percentage points), hematological malignancies (7–13 p.p.), malignancies of 
bone and cartilage (10–14 p.p.), thyroid gland cancers (5–9 p.p.) and kidney cancer (7–9 p.p.).
Discussion. Although survival rates are lower than in other European countries, survival of oncology patients in 
Poland has improved.
Conclusions
1. In Poland, survival of patients with majority of cancer types has improved.
2. The greatest increase in survival rates was observed for rare malignancies.
3. The improvement occurred during the time when the National Cancer Control Program was implemented.
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Introduction
In Poland, malignant neoplasms have become a still 
growing burden to the society on many levels, however, 
the most noticeable are health effects. Also in other (e.g. 
social, organizational, and financial) dimensions, cancers 
pose a challenge for the healthcare system. The anticipated 
increase in the number of cases, resulting from aging of 
modern societies, including the Polish population, but also 
from growing exposition to some risk factors, stimulates 
search for strategies that would prevent cancer effects [1, 
2]. These strategies are targeted mainly at popularization 
of primary [3] and secondary [4] prevention [3], but also at 
providing patients with equal accessibility of therapy [5], 
psychological care and rehabilitation.
Since funding of healthcare is limited, evidence-based 
assessment of each of these activities should be perfor-
med. In European countries, where national strategies for 
cancer control were implemented, incidence, mortality and 
5-year survival rates were deemed measures of healthcare 
intervention efficiency. Survival is one of the most impor-
tant synthetic measures of abilities and performance of 
healthcare.
Survival rates are a universal measure allowing asses-
sment of broadly understood healthcare and efficiency 
of treatment for particular diseases; they are used both in 
population studies, as well as in smaller, selected groups 
of patients. In clinical studies, patient survival is usually 
assessed according to Kaplan-Meier method, mostly to 
compare treatment results between specific medications 
or treatment regimes. These studies are usually conducted 
in small groups of patients and they do not reflect results 
obtained for a general population. Assessment of treatment 
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efficiency at the level of populations from various countries 
provides a different perspective. In such a case, especially 
when no population registry is available, survival analysis is 
performed via an indirect method, using MIR (mortality to 
incidence ratio), which is a kind of a surrogate for a 5-year 
survival rate. This approach was used to assess healthcare 
functioning in the scope of oncology in OECD countries [7].
In countries where cancer registries are held, population 
efficiency of cancer treatment is assessed based on the so-
-called 5-year survival rates. A 5-year horizon was determined 
arbitrarily in 1930-ies, when most treatment failures occurred 
within 5 years of diagnosis [8]. The observed survivals do not 
account for the processes of natural mortality causes not rela-
ted to cancer, which renders comparison in time and between 
populations difficult. Considering the natural mortality in the 
studied population allows obtaining a measure — relative 
survival — that is free of these limitations [9].
The last population survival rates for Poland presented 
in 2013 concerned only patients followed up until the end of 
2010 [10]. The main aim of this article is to present long-term 
tendency in curability of Polish patients diagnosed between 
1999–2010, for whom the treatment effects were evaluated 
based on the 5-year relative survival rates estimated after 
follow up until the end of 2015.
Materials and methods
Survival analysis was performed based on a set of cancer 
cases diagnosed in 1999–2010 and entered into the Polish 
National Cancer Registry. For over 20 years, the data in the 
Polish National Cancer Registry has been collected accor-
ding to guidelines of the International Agency for Research 
on Cancer (IARC), which guarantees its comparability in 
time. Analysis of the set quality is performed in real time; 
additionally, once a year, the whole set is verified against 
the international guidelines. Vital status of the patients was 
verified based on death registry until 31 December 2015, 
obtained from Statistics Poland.
The cancers were coded according to the Internatio-
nal Statistical Classification of Diseases and Related Health 
Problems (revision 10) valid in Poland [11]. The analysis 
was performed for all cancers combined and for 26 most 
frequent cancer localizations in adults.
The initial set covered 1,579,393 cases of cancer. Entries 
related to cancer cases in patients aged 0–14 were exclu-
ded from the analyzed set. Other exclusion criteria for the 
set included: cases registered based on autopsy or death 
certificate only (DCO), cases of skin cancers different than 
melanoma (C44) and in situ cancers (D00–D09), patients 
without PESEL (personal identity number) and patients for 
whom time interval between the date of disease onset and 
date of death was less than 30 days. Eventually, the analy-
sis included 1,297,779 cases aged 15–99, diagnosed with 
malignant neoplasms classified in the range of C00–C96 
(without skin cancer — C44) (Table I).
The estimated 5-year relative survival rates were cal-
culated as per Hakulinen method, using SURV3 software 
[12]. Lifespan tables for the Polish population between 
1999–2015 used in the analysis were obtained from Stati-
stics Poland in Warsaw. This analysis compares four 3-year 
periods covering patients diagnosed between 1999–2001, 
2002–2004, 2005–2007 and 2008–2010 and followed up 
until 31 December 2015.
Table I. Data quality indicators for patients diagnosed during 1999–2010
1999–2001 2002–2004 2005–2007 2008–2010
Number of cases in the NCR database 354,743 380,825 411,268 432,557
Cases excluded from the analysis
Number % Number % Number % Number %
No identity number — lost to follow-up 5258 1.5% 1189 0.3% 228 0.1% 115 0.03%
Death within 0–29 days 19,071 5.4% 23,972 6.3% 24,687 6.0% 23,684 5.5%
In situ cancers 2144 0.6% 3276 0.9% 4717 1.1% 6845 1.6%
DCO 23,756 6.7% 19,481 5.1% 12,227 3.0% 3192 0.7%
Age 0–14 2400 0.7% 2363 0.6% 2326 0.6% 2278 0.5%
Skin cancer (C44) 18,388 0.7% 22,609 0.6% 27,432 0.6% 29,454 0.5%
Cases included to the analysis
1999–2001 2002–2004 2005–2007 2008–2010
Number % Number % Number % Liczba %
All cases 282,490 79.6% 308,106 80.9% 339,954 82.7% 367,229 84.9%
Histopathology confirmation 201,005 71.2% 249,156 80.9% 285,494 84.0% 318,876 86.8%
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In the following Results, “survival rates” should be un-
derstood as “5-year relative survival rates.” 
Results
In Poland, 5-year survival rates for patients with all can-
cers increased in men from 32.9% (diagnosis in 1999–2001) 
to 41.3% (diagnosis in 2008–2010) (increase by 8.4 percen-
tage points); in women, the increase from 50.9% to 56.1% 
(increase by 5.1 p.p.), respectively, was observed.
Men
In male population (Table II, Fig. 1), the greatest survival 
rate increase was found for prostate cancer. Among patients 
diagnosed in the last analyzed period, the survival rate was 
14.9 percentage points higher than in the first analyzed 
period and equal to 75.8%.
Between 1999–2010 (follow up until the end of 2015), 
survival rates for Hodgkin’s lymphoma patients increased 
by 13 p.p. (from 69.2% to 82.2%), for patients with non-
-Hodgkin’s lymphoma by 10.9 p.p. (from 42.8% to 53.6%), 
with multiple myeloma by 9.5 p.p. (from 28.6% to 38.1%), 
for leukaemia patients (C91–C95) by 7.3 p.p. (from 37.7% 
to 45.0%), and for lymphatic leukaemia patients by 7 p.p. 
(46.8% to 53.9%). For myeloid leukaemia, the survival rate 
increased by 3 p.p. (from 25.1% to 28.1%).
Survival rate for male patients with bone and cartilage 
malignancies increased by 10.0 p.p. In patients with thyroid 
gland cancers diagnosed between 2008–2010, higher su-
rvival rates (84.8%) were observed as compared to patients 
diagnosed 8–10 years earlier: increase by 9.1 p.p. Impro-
vement of survival was also found in patients with kidney 
Table II. Five-year relative survival rates in Poland for patients at age 15–99 with diagnosis in one of four calendar period between 1999–2010
Site ICD-10 Year of 
diagnosis
Men Women
Number Rate 95% CI Number Rate 95% CI
All cancers C00-C96 1999–2001 142,816 32.9 32.6 – 33.2 139,674 50.9 50.6 – 51.2
  2002–2004 156,512 36.3 36.0 – 36.5 151,594 53.1 52.9 – 53.4
  2005–2007 171,933 39.9 39.7 – 40.2 168,021 55.1 54.8 – 55.3
  2008–2010 184,423 41.3 41.0 – 41.5 182,806 56.1 55.8 – 56.3
Lip, oral cavity and 
pharynx
 
C00-C14 1999–2001 6439 36.5 35.2 – 37.7 1858 51.3 48.8 – 53.8
 2002–2004 6720 35.6 34.3 – 36.8 2207 53.5 51.2 – 55.7
  2005–2007 7310 36.1 34.9 – 37.3 2416 53.2 51.0 – 55.3
  2008–2010 7867 35.8 34.6 – 36.9 2876 52.9 50.9 – 54.9
Oesophagus C15 1999–2001 2579 7.2 6.2 – 8.3 579 11.3 8.6 – 14.1
  2002–2004 2672 6.4 5.4 – 7.4 641 11.9 9.2 – 14.6
  2005–2007 2687 8.2 7.1 – 9.3 660 12.0 9.4 – 14.7
  2008–2010 2682 7.1 6.1 – 8.2 703 13.2 10.5 – 15.9
Stomach C16 1999–2001 8515 15.2 14.4 – 16.0 4657 18.8 17.6 – 20.0
  2002–2004 8698 15.9 15.1 – 16.7 4719 20.3 19.0 – 21.5
  2005–2007 9128 19.5 18.6 – 20.4 5011 23.7 22.5 – 25.0
  2008–2010 9449 18.9 18.0 – 19.7 5117 24.3 23.1 – 25.6
Colon C18-C19 1999–2001 9171 41.8 40.7 – 42.9 8971 44.2 43.0 – 45.3
  2002–2004 11,215 44.9 43.9 – 45.9 10,593 48.2 47.1 – 49.2
  2005–2007 13,549 48.1 47.1 – 49.0 12,312 50.8 49.8 – 51.8
  2008–2010 15,230 48.3 47.4 – 49.2 13,564 52.4 51.4 – 53.3
Rectum and anus C20-C21 1999–2001 7476 38.6 37.4 – 39.8 5733 41.6 40.2 – 43.0
 2002–2004 8300 41.4 40.2 – 42.6 6328 45.7 44.3 – 47.0
  2005–2007 9576 44.7 43.6 – 45.8 6716 49.0 47.7 – 50.4
  2008–2010 9868 45.0 43.9 – 46.1 7013 48.4 47.1 – 49.7
Colorectum C18-C21 1999–2001 16,647 40.4 39.5 – 41.2 14,704 43.2 42.3 – 44.0
  2002–2004 19,515 43.4 42.6 – 44.2 16,921 47.2 46.4 – 48.1
  2005–2007 23,125 46.7 45.9 – 47.4 19,028 50.2 49.4 – 51.0
  2008–2010 25,098 47.0 46.3 – 47.7 20,577 51.0 50.2 – 51.8
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Site ICD-10 Year of 
diagnosis
Men Women
Number Rate 95% CI Number Rate 95% CI
Gallbladder C23-C24 1999–2001 1060 14.7 12.4 – 17.0 3086 11.5 10.3 – 12.7
  2002–2004 1115 14.1 11.9 – 16.3 3014 12.7 11.4 – 14.0
  2005–2007 1145 18.8 16.3 – 21.3 2968 14.8 13.5 – 16.2
  2008–2010 1226 16.8 14.6 – 19.1 3013 14.1 12.8 – 15.5
Larynx C32 1999–2001 6742 49.1 47.7 – 50.4 815 58.8 55.1 – 62.4
  2002–2004 6554 49.3 47.9 – 50.6 902 61.7 58.3 – 65.2
  2005–2007 6658 48.7 47.4 – 50.1 942 61.3 57.9 – 64.6
  2008–2010 6335 49.1 47.7 – 50.4 891 58.8 55.3 – 62.3
Lung and trachea C33-C34 1999–2001 38,438 11.3 11.0 – 11.7 10,160 16.8 16.0 – 17.5 
  2002–2004 39,505 11.8 11.4 – 12.1 11,750 17.5 16.8 – 18.2
  2005–2007 40,306 13.8 13.4 – 14.1 13,921 19.3 18.6 – 20.0
  2008–2010 40,243 12.6 12.2 – 12.9 16,226 18.5 17.9 – 19.2
Bones and cartilage C40-C41 1999–2001 531 40.8 36.3 – 45.2 403 46.9 41.7 – 52.1
  2002–2004 495 49.5 44.8 – 54.2 372 51.4 45.9 – 56.8
  2005–2007 477 52.5 47.7 – 57.3 385 57.8 52.6 – 63.1
  2008–2010 472 50.7 45.9 – 55.6 408 61.0 55.9 – 66.1
Melanoma C43 1999–2001 2314 52.0 49.7 – 54.2 2880 66.0 64.1 – 67.9
  2002–2004 2748 52.1 50.0 – 54.1 3350 67.3 65.5 – 69.0
  2005–2007 3206 55.2 53.3 – 57.1 3705 69.8 68.1 – 71.4
  2008–2010 3533 57.2 55.4 – 59.0 4151 71.6 70.1 – 73.2
Breast C50 1999–2001 34,780 73.0 72.5 – 73.6
  2002–2004 37,173 75.3 74.8 – 75.8
  2005–2007 42,235 77.0 76.6 – 77.5
  2008–2010 46,633 78.5 78.1 – 79.0
Cervix C53 1999–2001 10,367 53.7 52.7 – 54.7
  2002–2004 10,155 54.2 53.2 – 55.3
  2005–2007 9905 55.6 54.6 – 56.7
  2008–2010 9486 56.4 55.4 – 57.5
Uterus C54 1999–2001 10,624 74.7 73.8 – 75.6
  2002–2004 12,302 76.0 75.1 – 76.9
  2005–2007 13,680 76.9 76.1 – 77.8
  2008–2010 15,366 77.1 76.3 – 77.8
Ovary C56 1999–2001 10,352 39.2 38.2 – 40.2
  2002–2004 10,958 39.5 38.5 – 40.5
  2005–2007 11,249 41.1 40.1 – 42.0
  2008–2010 11,661 43.9 42.9 – 44.9
Prostate C61 1999–2001 14,426 61.0 60.0 – 61.9
  2002–2004 18,891 71.7 70.9 – 72.5
  2005–2007 23,969 74.2 73.5 – 74.8
  2008–2010 28,354 75.8 75.2 – 76.5
Testis C62 1999–2001 1956 87.0 85.3 – 88.6
  2002–2004 2403 88.2 86.8 – 89.6
  2005–2007 2688 89.4 88.1 – 90.7
  2008–2010 3238 91.6 90.5 – 92.6
Table II. Five-year relative survival rates in Poland for patients at age 15–99 with diagnosis in one of four calendar period between 1999–2010. Cont.
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Site ICD-10 Year of 
diagnosis
Men Women
Number Rate 95% CI Number Rate 95% CI
Kidney C64-C65 1999–2001 6206 51.2 49.8 – 52.6 4200 57.4 55.8 – 59.1
  2002–2004 6824 52.3 51.0 – 53.7 4610 60.8 59.2 – 62.3
  2005–2007 7375 54.7 53.5 – 56.0 4975 63.3 61.8 – 64.8
  2008–2010 8483 58.6 57.4 – 59.7 5788 66.7 65.3 – 68.0
Urinary bladder C67 1999–2001 10,952 52.5 51.4 – 53.5 2586 58.0 55.8 – 60.1
  2002–2004 12,241 53.6 52.6 – 54.6 3081 60.1 58.1 – 62.0
  2005–2007 13,164 56.3 55.3 – 57.3 3621 63.0 61.3 – 64.8
  2008–2010 14,710 54.9 53.9 – 55.8 4189 61.9 60.2 – 63.5
Thyroid C73 1999–2001 728 75.7 72.2 – 79.3 3595 89.8 88.7 – 91.0
  2002–2004 873 79.1 76.0 – 82.2 4268 92.6 91.6 – 93.6
  2005–2007 968 83.4 80.6 – 86.2 4603 94.0 93.1 – 94.9
  2008–2010 1086 84.8 82.2 – 87.4 5347 95.1 94.4 – 95.9
Hodgkin 
lymphoma
 
C81 1999–2001 1228 69.2 66.4 – 72.1 1090 76.4 73.7 – 79.1
 2002–2004 1250 75.2 72.6 – 77.9 1164 82.6 80.3 – 85.0
  2005–2007 1153 78.8 76.2 – 81.3 1156 82.6 80.2 – 84.9
  2008–2010 1091 82.2 79.7 – 84.7 1057 87.2 85.0 – 89.4
Non-Hodgkin 
lymphoma
C82-C85 1999–2001 2969 42.8 40.8 – 44.7 2710 48.7 46.7 – 50.8
  2002–2004 3490 44.2 42.4 – 46.0 2998 50.1 48.1 – 52.0
  2005–2007 3776 47.9 46.2 – 49.7 3439 54.5 52.7 – 56.3
  2008–2010 4030 53.6 51.9 – 55.3 3854 58.4 56.7 – 60.1
Multiple myeloma C90 1999–2001 1094 28.6 25.6 – 31.5 1306 30.0 27.3 – 32.7
  2002–2004 1401 31.2 28.5 – 33.8 1624 32.7 30.3 – 35.2
  2005–2007 1624 33.0 30.5 – 35.5 1814 35.7 33.3 – 38.1
  2008–2010 1722 38.1 35.5 – 40.6 2025 39.8 37.5 – 42.2
Lymphoid 
leukaemia
C91 1999–2001 1691 46.8 44.2 – 49.5 1406 54.0 51.0 – 56.9
  2002–2004 2116 48.3 45.9 – 50.7 1546 54.6 51.9 – 57.4
  2005–2007 2394 51.9 49.7 – 54.2 1857 60.2 57.7 – 62.7
  2008–2010 2810 53.9 51.8 – 55.9 2092 59.6 57.2 – 62.0
Myeloid leukaemia C92 1999–2001 1136 25.1 22.4 – 27.8 1085 24.8 22.1 – 27.6
  2002–2004 1293 25.2 22.7 – 27.8 1196 29.7 26.9 – 32.4
  2005–2007 1454 30.9 28.3 – 33.5 1346 34.7 32.0 – 37.4
  2008–2010 1478 28.1 25.6 – 30.6 1366 34.5 31.8 – 37.2
All leukaemias C91-C95 1999–2001 3053 37.7 35.8 – 39.6 2737 41.1 39.1 – 43.1
  2002–2004 3649 39.4 37.6 – 41.1 2953 43.4 41.5 – 45.4
  2005–2007 4096 43.5 41.8 – 45.2 3398 49.0 47.2 – 50.9
  2008–2010 4621 45.0 43.4 – 46.6 3803 49.3 47.6 – 51.1
cancer: the survival rate increased from 52.1% to 58.6% 
(increase by 7.4 p.p.).
Among patients with colorectal cancer (C18–C21), the 
survival rates increased from 40.4% to 47.9% (increase by 
6.6 p.p.). The increase was observed for both, colon (C18–
C19), and rectal cancer (C20–C21). Survival in patients with 
colon cancer diagnosed in the last analyzed period was 6.5 
p.p. higher as compared to patients diagnosed in the initial 
period included in the analysis; and for patients with rectal 
cancer, the respective difference was 6.4 p.p.
For patients diagnosed in the discussed decade, the 
increase in rate value by more than 5 p.p. was also observed 
Table II. Five-year relative survival rates in Poland for patients at age 15–99 with diagnosis in one of four calendar period between 1999–2010. Cont.
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Figure 1. Trends in survival for patients at age 15–99 diagnosed in Poland during 1999–2001, 2002–2004, 2005–2007 and 2008–2010 by selected 
cancers
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for melanoma cases. The improvement was also seen for 
patients with testicle cancer (increase from 87.0% to 91.6% 
— change by 4.6 p.p.).
In the case of patients with other cancers (stomach, 
gall bladder, lung, larynx, oesophagus cancer), the survival 
rate changes were minor (see Table II), and 5-year survival 
did not exceed 25%. Among patients diagnosed over the 
last 3-year period, 5-year survival rates for patients with the 
above-mentioned cancers were as follows: stomach: 18.9%, 
gallbladder — 16.8%, lung — 12.6%, oesophagus — 7.1%. 
The lowest survival rates were observed for patients with 
oesophagus cancer (7.1%) and no progress in treatment of 
cancer in this localization was observed. For urinary blad-
der and larynx cancer, the survival rates oscillated around 
50% (54.9% and 49.1%, respectively), however, advance in 
curability of urinary bladder cancer was only 2.4 p.p., and for 
larynx cancer, no change was noted. No advance was found 
in therapy for patients with oral cavity and pharynx cancer; 
the survival rate remained at a similar level over the whole 
analysis period — at about 35%.
Women
When survival rates for patients diagnosed in 1999–2010 
are compared in female population (Table II, Fig. 1), the gre-
atest improvement was observed in treatment of patients 
with bone and cartilage tumors (increase by 14.1 p.p. to 61%) 
and hematopoietic and lymphatic tissue malignancies: Hodg-
kin’s lymphoma (increase by 10.8 p.p., to 87.2%), multiple 
myeloma (increase by 9.8 p.p., to 39.8%), myeloid leukaemia 
(increase by 9.7 p.p., to 34.5%), non-Hodgkin’s lymphoma (in-
crease by 9.7 p.p., to 58,4%), leukaemias combined (increase 
by 8.3 p.p., to 49.3%), lymphatic leukaemia (increase by 5.6 
p.p., to 59.6%). Increase in survival rates was also observed in 
patients with kidney cancer (increase by 9.3 p.p., to 66.7%).
Among women, a great increase in survival rates was 
also observed among patients with colorectal cancer (C18–
C21) — increase by 7.8 p.p. (to 51.0%), with 8.2 p.p. for colon 
cancer (C18–C19) (to 52.4%) and 6.8 p.p. for rectal cancer 
(to 48.4%). Improvement was obtained in survival rates for 
patients with melanoma (by 5.7 p.p., to 71.6%), as well as 
with stomach cancer (by 5.6 p.p., to 24.3%) and breast cancer 
(by 5.5 p.p., to 78.5%).
Improvement in 5-year survival rates by slightly more 
than 5 p.p. was found in female patients diagnosed in 2008–
2010 with stomach cancer (18.8% vs 24.3%), breast cancer 
(73.0% vs 78.5%) and thyroid gland cancer (89.8% vs 95.1%). 
A minor improvement over the discussed period was also 
noted for treatment of ovarian cancer (4.7 p.p., to 43.5%) 
and urinary bladder cancer (3.9 p.p., to 61.9%). Moreover, 
the survival rate improved for patients with cervical cancer 
by 2.8 p.p. (53.7% vs 56.4%), with gallbladder cancer by 2.6 
p.p. (11.5% vs 14.1%), and with uterus cancer by 2.4 p.p. 
(74.7% vs 77.1%). Increase in the survival rate for patients 
with oesophagus, lung, oral cavity and pharynx cancer was 
low (less than 2 p.p.). The only cancer with no change in the 
survival rate was larynx cancer (about 59%).
Discussion
In the Polish National Cancer Registry, two assessments 
of cancer patients’ survival rates for the whole Poland were 
performed [13, 14]. Both analyses included patients regi-
stered in the Polish National Cancer Registry, for whom 
follow up was finished at the end of 2007 and 2010. Fulfilling 
the postulate to systematically publish the survival rates 
for patients from the Polish population, the authors have 
decided to compare four periods of diagnosis (1999–2001, 
2002–2004, 2005–2007 and 2008–2010; the follow up was fi-
nished in 2006, 2009, 2012 and 2015, respectively) in order to 
trace changes in survival of Polish patients over the decade.
The presented population 5-year relative survival rates 
cover a period before and after enforcement of an act on es-
tablishing the National Cancer Control Program in 2006 [15]. 
Patients diagnosed in 1999–2001 were treated before the 
end of 2006 and enforcement of the Act did not influence 
their treatment results. Comparison of survival rates betwe-
en the first (diagnosis in 1999–2001) and the last analyzed 
period (diagnosis 2008–2010) indicates that in the majority 
of analyzed cancers and cancers in general, significant im-
provement occurred (increase by 8.4 percentage points in 
men — from 32.9% to 41.3% and by 5 percentage points in 
women — from 50.9% to 56.3%). The difference between 
general survival rates for men and women results from 
the structure of cancer incidence in the Polish population. 
Among cancers with favorable prognosis (relative survival 
rates above 50%), only two cancer types in men (prostate 
with a rate of 75,8% and urinary bladder with a rate of 54.9%) 
and four cancer types in women (uterus 77.1%, breast 78.5%, 
cervix 56.4%, colorectal cancer — 51.0%) are among the 5 
most frequent cancers. At the same time, five most frequent 
cancers include lung cancer (survival rate 12.6% in men, 
18.5% in women) and stomach cancer (18.9% and 24.3%, 
respectively), which are cancers with very unfavorable pro-
gnosis [10] (Fig. 2). Similar limitations must be considered 
upon comparison of cumulative survival rates for Poland and 
other European countries [16], since they do not account for 
the incidence structure in the compared countries: in men, 
prostate cancer prevails in the western countries (24%), 
however, in Poland, lung cancer is the most frequent cancer 
in men (18.5%); higher percentage of breast cancer in the 
incidence structure is seen in women from West European 
countries (30%) than from Poland (22%) [17, 18].
Despite the use of a different measures (standardized 
net relative survival rate representing cumulative probability 
of surviving 5 or more years, assuming that cancer is the only 
cause of death), assessment of survival of oncology patients 
in Poland as compared to other countries, published within 
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the scope of Concord-3 project [19], was consistent with 
results obtained in the analysis performed by the Polish 
National Cancer Registry. For all cancers analyzed in the 
Concord-3 study (15 locations in adults), net 5-year survival 
rates in Poland were lower than in the majority of European 
countries. Concord-3 study (diagnosis 2000–2014), similarly 
like the results presented herein (diagnosis 1999–2010), 
documents a major improvement that occurred in Poland 
in the first decade of the 21st century.
Direct comparison of survival rates obtained using two 
different methods (Hakulinen method and Pohar Perme 
estimator) [12, 20] is not justified, however, comparison of 
tendencies observed over time indicates that improvement 
in treatment of cancers has taken place in Poland, regardless 
of the measurement method. The tendencies in the obse-
rved changes for the two studies are similar, in terms of both, 
direction and the magnitude of change. In Concord-3 study, 
in 2000–2014, increase in net survival rate by about 6–8 p.p. 
for colorectal cancer (both sexes) was shown (increase from 
45.3% to 52,9% for colon cancer and from 42.5% to 48.4% 
for rectal cancer), whereas in the PNCR analysis, the increase 
between the first and the last analyzed period (1999–2001 vs 
2008–2010) was, respectively, 6.5 p.p. and 6.4 p.p. for men, 
and 8.2 p.p. and 6.8 p.p. for women. For the other analyzed 
cancers, improvement of survival was also found: stomach 
cancer — according to Concord-3, increase by 5 p.p. (from 
15.9% to 19.9%), according to PNCR, increase by 3.7 p.p. in 
men and by 5.5 p.p. in women; lung cancer — according 
to Concord-3, increase by 2.3 p.p. (from 12.1% to 14.4%), 
according to PNCR, increase by 1.3 p.p. in men and 1.8 p.p. 
in women; breast cancer — according to Concord-3, increase 
by 5.2 p.p. (from 71.3% to 76.5%), according to PNCR, incre-
ase by 5.5 p.p.; cervical cancer — according to Concord-3, 
increase by 3.5 p.p. (from 51.6% to 55.1%), according to 
PNCR, increase by 2.8 p.p.; ovarian cancer — according 
to Concord-3, increase by 4.8 p.p. (from 32.7% to 37.5%), 
according to PNCR, 4.7 p.p.
In the case of prostate cancer patients, in Concord-3 
study, the survival rates increased by 9.3 p.p. (68.8 vs 78.1%) 
whereas in PNCR analysis, the increase was estimated as 14.9 
p.p. Such a significant increase results probably from more 
and more common opportunistic screening for prostate 
cancer (assaying PSA level and using TRUS examination for 
diagnostic purposes). According to Prajsner et al. who ana-
lyzed the results of PolSenior study performed in 2007–2012 
[21], 41.2% of older men (aged 65–74) and 24.8% of younger 
men (aged 55–59) had PSA level assayed. Early beginning of 
prostate cancer diagnostics may lead to detection of early 
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Figure 2. Trends in survival for patients at age 15–99 diagnosed in Poland during 1999–2001, 2002–2004, 2005–2007 and 2008–2010 by selected 
cancers
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non-symptomatic cancer, which in turn may result in the 
so-called overtreatment, and to fast change in the value of 
survival rates by detection of the disease before manifesta-
tion of clinical symptoms (the so-called lead time bias). In 
2000 in the U.S., Medicare started funding an annual PSA 
examination, which resulted in rapid increase in incidence 
and had no effect on mortality [22].
The greatest improvement occurred for treatment of 
relatively rare cancers in Poland. 5-year relative survival rates 
for patients with Hodgkin’s lymphoma, non-Hodgkin’s lym-
phoma and with bone and cartilage malignancies increased 
in the analyzed years by more than 10 percentage points. 
Improvement was also obtained in treatment of patients 
with myeloma and some leukaemia types.
The presented results are a significant generalization 
and may not be referred to individual clinical situations. The 
discussed analysis is a population-based assessment of onco-
logical care in Poland. Over the last two decades, a significant 
improvement in diagnostics and therapy of cancers occurred 
globally, hence improving both prognosis and patient su-
rvival. In Poland, high cost of modern therapies is still a big 
problem, which significantly limits and delays their common 
use. Although the survival rates are lower than in other coun-
tries, the increase in their values observed in the first decade 
of the 21st century may result from activities within the scope 
of the National Cancer Control Program enforced in 2006.
Conclusions
1. Over the discussed period, significant improvement in 
survival for the majority of cancers in Poland occurred, 
although survival rates for Poland are still lower than 
those for other European countries.
2. The presented results are consistent with results obta-
ined within the scope of the international CONCORD-3 
project (in terms of both, rate values and tendency over 
time).
3. Especially high increase in survival rates for patients 
with prostate cancer should be related to growing usage 
of PSA testing and TRUS examination and hence with 
detection of early forms of this cancer.
4. The highest increase in the survival rate values was 
observed for rare cancers (Hodgkin’s lymphoma, non-
-Hodgkin’s lymphoma, bone and cartilage malignancies 
and some leukaemias).
5. It seems that the National Cancer Control Program 
(2006–2015) influenced improvement in efficiency of 
treatment of malignant neoplasms in Poland.
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